Приказ основних података о документу
Quinoline-Conjugated Ruthenacarboranes: Toward Hybrid Drugs with a Dual Mode of Action.
dc.creator | Gozzi, Marta | |
dc.creator | Murganic, Blagoje | |
dc.creator | Drača, Dijana | |
dc.creator | Popp, John | |
dc.creator | Coburger, Peter | |
dc.creator | Maksimović-Ivanić, Danijela | |
dc.creator | Mijatović, Sanja | |
dc.creator | Hey-Hawkins, Evamarie | |
dc.date.accessioned | 2019-12-05T14:35:46Z | |
dc.date.available | 2019-12-05T14:35:46Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201900349 | |
dc.identifier.uri | https://radar.ibiss.bg.ac.rs/handle/123456789/3534 | |
dc.description.abstract | The role of autophagy in cancer is often complex, ranging from tumor-promoting to -suppressing effects. In this study, two novel hybrid molecules were designed, containing a ruthenacarborane fragment conjugated with a known modulator of autophagy, namely a quinoline derivative. The complex closo-[3-(η6 -p-cymene)-1-(quinolin-8-yl-acetate)-3,1,2-RuC2 B9 H10 ] (4) showed a dual mode of action against the LN229 (human glioblastoma) cell line, where it inhibited tumor-promoting autophagy, and strongly inhibited cell proliferation, de facto blocking cellular division. These results, together with the tendency to spontaneously form nanoparticles in aqueous solution, make complex 4 a very promising drug candidate for further studies in vivo, for the treatment of autophagy-prone glioblastomas. | en |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173013/RS// | |
dc.relation | Saxon State Ministry for Sciences and the Arts. Grant Number: LAU-R-N-11-2-0615 | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | ChemMedChem | |
dc.subject | Autophagy | |
dc.subject | Glioblastoma | |
dc.subject | Quinoline | |
dc.subject | Ruthenacarborane | |
dc.subject | Self-assembly | |
dc.title | Quinoline-Conjugated Ruthenacarboranes: Toward Hybrid Drugs with a Dual Mode of Action. | en |
dc.type | article | en |
dc.rights.license | BY | |
dcterms.abstract | Цобургер, Петер; Попп, Јохн; Максимовић-Иванић, Данијела; Мијатовић, Сања; Хеy-Хаwкинс, Евамарие; Гоззи, Марта; Драча, Дијана; Мурганиц, Благоје; | |
dc.rights.holder | © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. | |
dc.identifier.doi | 10.1002/cmdc.201900349 | |
dc.identifier.pmid | 31675152 | |
dc.identifier.scopus | 2-s2.0-85075377850 | |
dc.identifier.wos | 000497336700001 | |
dc.citation.apa | Gozzi, M., Murganic, B., Drača, D., Popp, J., Coburger, P., Maksimović-Ivanić, D., et al. (2019). Quinoline-Conjugated Ruthenacarboranes: Toward Hybrid Drugs with a Dual Mode of Action. ChemMedChem, cmdc.201900349. | |
dc.citation.vancouver | Gozzi M, Murganic B, Drača D, Popp J, Coburger P, Maksimović-Ivanić D, Mijatović S, Hey-Hawkins E. Quinoline-Conjugated Ruthenacarboranes: Toward Hybrid Drugs with a Dual Mode of Action. ChemMedChem. 2019;cmdc.201900349. | |
dc.type.version | acceptedVersion | |
dc.identifier.fulltext | https://radar.ibiss.bg.ac.rs/bitstream/id/5750/ChemMedChem_2019-2.pdf | |
dc.citation.rank | M22 |